News Release

Printer Friendly Version View printer-friendly version
<< Back
Cidara Therapeutics to Present Data from Antifungal Drug Development Program at ICAAC
September 9, 2014 at 3:48 PM EDT

Results from nonclinical studies of Cidara’s lead candidate CD101 IV (formerly biafungin), a novel, long-acting echinocandin, will be presented this week at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Washington D.C. Four posters and one abstract regarding CD101 IV have been accepted for presentation.

Kieren Marr, M.D., professor of medicine and oncology, and director of the transplant and oncology infectious diseases program at the Johns Hopkins University School of Medicine and advisor to Cidara, stated, “There remains significant unmet need for novel drugs to treat life-threatening, invasive fungal infections. A long-acting echinocandin would represent a major addition to our antifungal repertoire by enabling easier completion of treatment without antifungal class switching, potentially enabling earlier discharge of patients and better prevention strategies in high risk patients.”

The presentations are as follows:

Sunday, September 7th

Poster Presentations 082 – Pharmacokinetics/Pharmacodynamics of Antifungal Agents
(11:00 a.m. – 1:00 p.m.)

  • A-693: CD101, a Novel Echinocandin, Displays an Uncommonly Long Half-life in Multiple Species; K. James, R. Krishnan, C. Laudeman, K. Polowy, A. Vaidya
  • A-694: CD101, a Novel Echinocandin, Displays a Long Half-life in the Chimpanzee, Suggesting a Once-Weekly IV Dosing Option; K. James, R. Krishnan, S. Smith, C. Laudeman, K. Polowy, A. Vaidya

Poster Presentations 109 – Fungal Epidemiology (11:00 a.m. – 1:00 p.m.)

  • M-1082: Activity Of A Novel Echinocandin CD101 Tested Against Most Common Candida And Aspergillus Species, Including Echinocandin- And Azole-resistant Strains; M. Castanheira, S. Messer, P. Rhomberg, R. Jones, M. Pfaller

Monday, September 8th

Poster Presentation 171 – New Antifungal Agents on the Horizon (11:00 a.m. – 1:00 p.m.)

  • F-1592: CD101, a Novel Echinocandin, Displays Excellent Stability in Plasma, Aqueous Solution, and at Elevated Temperature; R. Krishnan, K. James, S. Smith, C. Laudeman, A. Vaidya, B. Bryant, K. Polowy

Published Abstract:

  • Single-dose Pharmacokinetics of CD101, a Novel Echinocandin, after Subcutaneous Administration in Rat and Monkey; K. James, R. Krishnan, K. Polowy, C. Laudeman